Bjorn Henning Gronberg, MD, PhD, on SCLC: Adjuvant Immunotherapy After CRT
2025 ASCO Annual Meeting
Bjorn Henning Gronberg, MD, PhD, of Norwegian University of Science and Technology (NTNU) and St. Olavs Hospital, presents phase II findings on the efficacy of atezolizumab after chemoradiotherapy (CRT) in limited-stage small cell lung cancer (SCLC) (LBA8005).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We enrolled 216 patients at 37 hospitals in six countries of Europe, and out of those, 170 patients were randomized to receive either one year of atezolizumab or observation. The main endpoint was overall survival, and unfortunately we did not see any signal of an effect, neither for progression-free survival, so this is clearly a negative trial. Looking at subgroups, we do see that there are some differences in the effect depending on gender. Among women, patients on the observation arm lived much longer than expected, while among men there appears to be a signal of an effect. We also see that the choice of platinum had some influence on the survival curves. We see that among patients who received carboplatin, maybe there's a signal of an effect quite similar to what we actually saw also in the ADRIATIC trial. Median treatment time was 8 courses. Overall, there were more side effects in the experimental arm, but maybe not any single adverse event—it's more the totality. On the other hand, patients on the observation arm didn't meet the investigators as often as the patients who came regularly for infusions of atezolizumab. I think overall this study shows that the concept of adding checkpoint inhibitors after chemoradiated therapy in limited-stage small cell lung cancer is tolerable, even if this intervention did not prolong PFS or overall survival.
The ASCO Post Staff
Elena Elez, MD, PhD, of Vall d’Hebron Institute of Oncology, presents updated overall survival data as well as progression-free survival data from the BREAKWATER trial of the first-line use of encorafenib, cetuximab, and mFOLFOX6 in BRAF V600E–mutant metastatic colorectal cancer (LBA3500).
The ASCO Post Staff
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, describes the use of a multimodal artificial intelligence (AI) model to identify benefit from second-generation androgen receptor pathway inhibitors in patients with high-risk nonmetastatic prostate cancer participating in the STAMPEDE trial (Abstract 5001).
The ASCO Post Staff
Constantine Si Lun Tam, MD, FRACP, FRCPA, MBBS, of Alfred Hospital and Monash University, reviews results from the 5-year follow-up of arm C of the SEQUOIA trial of treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7011).
The ASCO Post Staff
Sameek Roychowdhury, MD, PhD, of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University Wexner Medical Center, discusses a recently opened telemedicine clinical trial of pemigatinib in patients with advanced or metastatic FGFR-mutated pancreatic cancer, and the germination of a new initiative, TNT Cancer, which focuses on leveraging telemedicine to bring trials nationwide.
The ASCO Post Staff
Ruben A. Mesa, MD, of Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University School of Medicine, presents results from a phase III trial investigating the efficacy of ropeginterferon alfa-2b vs anagrelide for the treatment of essential thrombocythemia (Abstract 6500).